Overview
Employees
501-1000
Founded date
2011
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jan 23, 2025 | GC Cell Symposium with Bifarma Expands Global Impact and Reach for Immuncell-LC | YONGIN, South Korea, Jan. 23, 2025 /PRNewswire/ -- GC Cell, a leading cell and gene therapy company, announced the successful completion of its first thought leadership symposium in Jakarta, Indonesia. The event was organized in collaborati... |
| Sep 11, 2024 | GC Cell and PT Bifarma Adiluhung sign a licensing agreement for Immuncell-LC to expand access in Indonesia | YONGIN, South Korea, Sept. 11, 2024 /PRNewswire/ -- GC Cell, a leading innovator in cell therapy, has officially announced the execution of a landmark 'Technology Transfer and License Agreement' with PT Bifarma Adiluhung (Bifarma), a premie... |
| Jun 20, 2024 | GC Cell Signs an MOU with PT Bifarma Adiluhung, an affiliate of KALBE group | GC Cell and PT Bifarma Adiluhung announced a strategic partnership to facilitate the entry of 'Immuncell-LC', the only approved autologous T-cell therapy for HCC into the Indonesian market. YONGIN, South Korea, June 20, 2024 /PRNewswire/ --... |
| May 28, 2024 | GC Cell participates 2024 BIO International Convention, Unveiling its future Blueprint 2.0, as the First Korean Business Forum Sponsor | SAN DIEGO, May 28, 2024 /PRNewswire/ -- GC Cell, a leader in the cell and gene therapy (CGT) sector within the biopharmaceutical industry, proudly announces its role as the first Korean Business Forum sponsor at the upcoming 2024 BIO Intern... |
| Apr 2, 2024 | GC Cell to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024 | YONGIN, South Korea, April 2, 2024 /PRNewswire/ -- GC Cell, a fully integrated cell therapy pioneer has announced poster presentations from studies of its preclinical study of GL205 (GCC2005), a CD5 CAR-NK targeting malignant T-cell lymphom... |
| Feb 26, 2024 | GC Cell and BioCentriq® Execute Process Transfer Agreement in Anticipation of the U.S. entry of Immuncell-LC Inj. | Immuncell-LC Inj. is an autologous Cytokine Induced Killer (CIK) cell therapy approved for Commercial use in South Korea as an adjuvant cell therapy for the treatment of Hepatocellular Carcinoma (HCC) after curative resection and has receiv... |
| Jan 9, 2024 | GC Cell's Promising AB-201 Cancer Treatment to Begin Phase 1 Trials Using Lunit AI Platform | South Korea's first CAR-NK cell therapy cleared for human trials in Australia and domestically; Cancer Moonshot participant GC Cell partnering with medical AI leader Lunit to collaborate on AB-201 clinical development YONGIN, South Korea an... |
Reviews 0
FAQ about 지씨셀
When was 지씨셀 founded?
지씨셀 was founded in 2011.
What has the press written about 지씨셀?
Parsers VC has collected 8 articles mentioning 지씨셀, among them “GC Cell Symposium with Bifarma Expands Global Impact and Reach for Immuncell-LC” (Jan 23, 2025) and “GC Cell and PT Bifarma Adiluhung sign a licensing agreement for Immuncell-LC to expand access in Indonesia” (Sep 11, 2024).
Is 지씨셀 still active?
Yes, 지씨셀 is active; its latest activity on Parsers VC dates from Oct 29, 2025.